Assessment of serum level of insulin-like growth factor 1 in the Blood of gastric cancer patients

Assessment of insulin-like growth factor I and its signaling pathways in the serum and the tissue of gastric cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016080318745N10

Enrollment

Registered

2016-08-30

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer. Stomach, unspecified

Interventions

The patients with dyspepsia will be divided into two groups: non-gastric and gastric cancer. After inclusion, 10 cc of whole blood and the tumor tissue sample of all the patients under endoscopy will

Diagnosis

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include: 40-70 years old patients with dyspepsia; the patients with written consent; the patients with no history of cancer or special disease. Exclusion criteria include: the patients with diabetes type 1 or 2; the patients with obesity; the patients with smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum level assessment of insulin-like growth factor I. Timepoint: after endoscopy procedure. Method of measurement: Elizza.	—

Secondary

Measure	Time frame
The expression of the genes involved in insulin-like growth factor 1 signaling pathway. Timepoint: One time after sampling. Method of measurement: Real-time PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Mohammad Alizadeh

Cancer Research Center, Cancer Institute of Iran

aalizadeh@sina.tums.ac.ir+98 21 6119 2501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026